{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PPARG", "biomarkers", "drug sensitivity", "immunological function", "prognosis", "tumor microenvironment"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38044948", "DateRevised": {"Year": "2023", "Month": "12", "Day": "05"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "15"}], "Language": ["eng"], "ELocationID": ["1298341", "10.3389/fphar.2023.1298341"], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2023"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma.", "Pagination": {"StartPage": "1298341", "MedlinePgn": "1298341"}, "Abstract": {"AbstractText": ["Peroxisome proliferator-activated receptor gamma (PPARG), a key transcription factor involved in lipid metabolism and glucose homeostasis, has been implicated in various types of cancer. However, its precise role in cancer remains unclear. In this study, we conducted a comprehensive pan-cancer analysis of PPARG expression using various types of cancer obtained from public databases. We observed significant heterogeneity in PPARG expression across different types of cancer. The association between PPARG expression and patient prognosis was investigated using Cox proportional hazards regression models and survival analysis. Clinical features and protein expression levels in the cohort showed that PPARG expression was strongly associated, suggesting its potential as a therapeutic target. We also evaluated the prognostic potential of PPARG by analyzing immune infiltration and genomic stability. We experimentally validated the potential of PPARG as a therapeutic target by analyzing drug sensitivity profiles, molecular docking simulations, and <i>in vitro</i> cell proliferation assays associated with PPARG expression. We identified common expression patterns of PPARG with other genes involved in key carcinogenic pathways. This provides deeper insights into the molecular mechanisms underlying its carcinogenic role. Additionally, functional enrichment analysis revealed significant enrichment of genes related to drug metabolism, cell proliferation, and immune response pathways associated with PPARG. Our findings highlight the importance of PPARG in the broader biology of cancer and suggest its potential as a diagnostic and therapeutic target for specific types of cancer. The results of our study provide strong support for the potential role of PPARG as a promising prognostic biomarker and immunotherapeutic target across various types of cancer."], "CopyrightInformation": "Copyright \u00a9 2023 Ran, Hu, Wan, Kang, Zhou, Liu, Ma, Wang and Tang."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}], "LastName": "Ran", "ForeName": "Yunsheng", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}], "LastName": "Hu", "ForeName": "Chujiao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}], "LastName": "Wan", "ForeName": "Junzhao", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Kang", "ForeName": "Qian", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Acupuncture and Moxibustion, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Zhou", "ForeName": "Ruixian", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Liu", "ForeName": "Ping", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Ma", "ForeName": "Dan", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}], "LastName": "Wang", "ForeName": "Jianta", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education and Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, China."}], "LastName": "Tang", "ForeName": "Lei", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CZ declared a past co-authorship with the author DM to the handling editor."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Andersen D. K., Korc M., Petersen G. M., Eibl G., Li D., Rickels M. R., et al. (2017). Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 66, 1103\u20131110. 10.2337/db16-1477", "ArticleIdList": ["10.2337/db16-1477", "PMC5399609", "28507210"]}, {"Citation": "Baer C., Walter W., Hutter S., Twardziok S., Meggendorfer M., Kern W., et al. (2019). Somatic\" and \"pathogenic\" - is the classification strategy applicable in times of large-scale sequencing? Haematologica 104, 1515\u20131520. 10.3324/haematol.2019.218917", "ArticleIdList": ["10.3324/haematol.2019.218917", "PMC6669162", "31273095"]}, {"Citation": "Ballav S., Biswas B., Sahu V. K., Ranjan A., Basu S. (2022). PPAR-Gamma partial agonists in disease-fate decision with special reference to cancer. Cells 11, 3215. 10.3390/cells11203215", "ArticleIdList": ["10.3390/cells11203215", "PMC9601205", "36291082"]}, {"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. 10.3322/caac.21492", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Cagan A., Baez-Ortega A., Brzozowska N., Abascal F., Coorens T. H. H., Sanders M. A., et al. (2022). Somatic mutation rates scale with lifespan across mammals. Nature 604, 517\u2013524. 10.1038/s41586-022-04618-z", "ArticleIdList": ["10.1038/s41586-022-04618-z", "PMC9021023", "35418684"]}, {"Citation": "Chan A. W., Wong G. L., Chan H. Y., Tong J. H., Yu Y. H., Choi P. C., et al. (2017). Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 32, 667\u2013676. 10.1111/jgh.13536", "ArticleIdList": ["10.1111/jgh.13536", "27547913"]}, {"Citation": "Chandrashekar D. S., Karthikeyan S. K., Korla P. K., Patel H., Shovon A. R., Athar M., et al. (2022). UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327. 10.1016/j.neo.2022.01.001", "ArticleIdList": ["10.1016/j.neo.2022.01.001", "PMC8788199", "35078134"]}, {"Citation": "Chiu M., Mcbeth L., Sindhwani P., Hinds T. D. (2017). Deciphering the roles of thiazolidinediones and PPAR\u03b3 in bladder cancer. PPAR Res. 2017, 4810672. 10.1155/2017/4810672", "ArticleIdList": ["10.1155/2017/4810672", "PMC5350343", "28348577"]}, {"Citation": "Diesendruck Y., Benhar I. (2017). Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. Drug Resist Updat 30, 39\u201347. 10.1016/j.drup.2017.02.001", "ArticleIdList": ["10.1016/j.drup.2017.02.001", "28363334"]}, {"Citation": "Fusco M. J., West H. J., Walko C. M. (2021). Tumor mutation burden and cancer treatment. JAMA Oncol. 7, 316. 10.1001/jamaoncol.2020.6371", "ArticleIdList": ["10.1001/jamaoncol.2020.6371", "33331847"]}, {"Citation": "Galbraith L., Leung H. Y., Ahmad I. (2018). Lipid pathway deregulation in advanced prostate cancer. Pharmacol. Res. 131, 177\u2013184. 10.1016/j.phrs.2018.02.022", "ArticleIdList": ["10.1016/j.phrs.2018.02.022", "29466694"]}, {"Citation": "Hughes C. E., Nibbs R. J. B. (2018). A guide to chemokines and their receptors. FEBS J. 285, 2944\u20132971. 10.1111/febs.14466", "ArticleIdList": ["10.1111/febs.14466", "PMC6120486", "29637711"]}, {"Citation": "Hughes T. S., Giri P. K., de Vera I. M., Marciano D. P., Kuruvilla D. S., Shin Y., et al. (2014). An alternate binding site for PPAR\u03b3 ligands. Nat. Commun. 5, 3571. 10.1038/ncomms4571", "ArticleIdList": ["10.1038/ncomms4571", "PMC4070320", "24705063"]}, {"Citation": "Joshi H., Pal T., Ramaa C. S. (2014). A new dawn for the use of thiazolidinediones in cancer therapy. Expert Opin. Investig. Drugs 23, 501\u2013510. 10.1517/13543784.2014.884708", "ArticleIdList": ["10.1517/13543784.2014.884708", "24597633"]}, {"Citation": "Kesanakurti D., Maddirela D., Banasavadi-Siddegowda Y. K., Lai T. H., Qamri Z., Jacob N. K., et al. (2017). A novel interaction of PAK4 with PPAR\u03b3 to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene 36, 5309\u20135320. 10.1038/onc.2016.261", "ArticleIdList": ["10.1038/onc.2016.261", "PMC5599308", "28534509"]}, {"Citation": "Lewis J. D., Lichtenstein G. R., Deren J. J., Sands B. E., Hanauer S. B., Katz J. A., et al. (2008). Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134, 688\u2013695. 10.1053/j.gastro.2007.12.012", "ArticleIdList": ["10.1053/j.gastro.2007.12.012", "PMC2276587", "18325386"]}, {"Citation": "Lin L., Lin H., Wang L., Wang B., Hao X., Shi Y. (2015). miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer. Oncol. Rep. 34, 3088\u20133096. 10.3892/or.2015.4301", "ArticleIdList": ["10.3892/or.2015.4301", "26398698"]}, {"Citation": "Liu C., Tate T., Batourina E., Truschel S. T., Potter S., Adam M., et al. (2019). Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat. Commun. 10, 4589. 10.1038/s41467-019-12332-0", "ArticleIdList": ["10.1038/s41467-019-12332-0", "PMC6785552", "31597917"]}, {"Citation": "Ma D., Liu P., Hu C., Zhou Z., Wang P., Wang Y., et al. (2023). Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia. Oncogene 42, 124\u2013137. 10.1038/s41388-022-02536-y", "ArticleIdList": ["10.1038/s41388-022-02536-y", "36385374"]}, {"Citation": "Mal S., Dwivedi A. R., Kumar V., Kumar N., Kumar B., Kumar V. (2021). Role of peroxisome proliferator-activated receptor gamma (PPAR\u03b3) in different disease states: recent updates. Curr. Med. Chem. 28, 3193\u20133215. 10.2174/0929867327666200716113136", "ArticleIdList": ["10.2174/0929867327666200716113136", "32674727"]}, {"Citation": "Ma S., Zhou B., Yang Q., Pan Y., Yang W., Freedland S. J., et al. (2021). A transcriptional regulatory loop of master regulator transcription factors, PPARG, and fatty acid synthesis promotes esophageal adenocarcinoma. Cancer Res. 81, 1216\u20131229. 10.1158/0008-5472.CAN-20-0652", "ArticleIdList": ["10.1158/0008-5472.CAN-20-0652", "PMC8026506", "33402390"]}, {"Citation": "Menezes J., Diederich M. F. (2021). Bioactivity of natural biflavonoids in metabolism-related disease and cancer therapies. Pharmacol. Res. 167, 105525. 10.1016/j.phrs.2021.105525", "ArticleIdList": ["10.1016/j.phrs.2021.105525", "33667686"]}, {"Citation": "Mohs A., Kuttkat N., Reissing J., Zimmermann H. W., Sonntag R., Proudfoot A., et al. (2017). Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J. Hepatol. 66, 743\u2013753. 10.1016/j.jhep.2016.12.011", "ArticleIdList": ["10.1016/j.jhep.2016.12.011", "28011329"]}, {"Citation": "Mukherjee R., Jow L., Croston G. E., Paterniti J. R., JR. (1997). Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 272, 8071\u20138076. 10.1074/jbc.272.12.8071", "ArticleIdList": ["10.1074/jbc.272.12.8071", "9065481"]}, {"Citation": "Mun E. J., Babiker H. M., Weinberg U., Kirson E. D., von Hoff D. D. (2018). Tumor-treating fields: a fourth modality in cancer treatment. Clin. Cancer Res. 24, 266\u2013275. 10.1158/1078-0432.CCR-17-1117", "ArticleIdList": ["10.1158/1078-0432.CCR-17-1117", "28765323"]}, {"Citation": "Park S. H., Choi H. J., Yang H., Do K. H., Kim J., Lee D. W., et al. (2010). Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 285, 35330\u201335339. 10.1074/jbc.M110.136259", "ArticleIdList": ["10.1074/jbc.M110.136259", "PMC2975157", "20829347"]}, {"Citation": "Petri B., Sanz M. J. (2018). Neutrophil chemotaxis. Cell Tissue Res. 371, 425\u2013436. 10.1007/s00441-017-2776-8", "ArticleIdList": ["10.1007/s00441-017-2776-8", "29350282"]}, {"Citation": "Roudko V., Bozkus C. C., Orfanelli T., Mcclain C. B., Carr C., O'Donnell T., et al. (2020). Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183, 1634\u20131649. 10.1016/j.cell.2020.11.004", "ArticleIdList": ["10.1016/j.cell.2020.11.004", "PMC8025604", "33259803"]}, {"Citation": "Ryu S., Kim D. S., Lee M. W., Lee J. W., Sung K. W., Koo H. H., et al. (2018). Anti-leukemic effects of PPAR\u03b3 ligands. Cancer Lett. 418, 10\u201319. 10.1016/j.canlet.2018.01.020", "ArticleIdList": ["10.1016/j.canlet.2018.01.020", "29331412"]}, {"Citation": "Shao W., Kuhn C., Mayr D., Ditsch N., Kailuwait M., Wolf V., et al. (2020). Cytoplasmic PPAR\u03b3 is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. J. Transl. Med. 18, 94. 10.1186/s12967-020-02271-6", "ArticleIdList": ["10.1186/s12967-020-02271-6", "PMC7035771", "32085795"]}, {"Citation": "Sharma P., Goswami S., Raychaudhuri D., Siddiqui B. A., Singh P., Nagarajan A., et al. (2023). Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669. 10.1016/j.cell.2023.03.006", "ArticleIdList": ["10.1016/j.cell.2023.03.006", "37059068"]}, {"Citation": "Shu Y., Lu Y., Pang X., Zheng W., Huang Y., Li J., et al. (2016). Phosphorylation of PPAR\u03b3 at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4. Oncotarget 7, 76984\u201376994. 10.18632/oncotarget.12764", "ArticleIdList": ["10.18632/oncotarget.12764", "PMC5363564", "27769068"]}, {"Citation": "Tian J., Hu L., Li X., Geng J., Dai M., Bai X. (2022). Retraction Note: MicroRNA-130b promotes lung cancer progression via PPAR\u03b3/VEGF-A/BCL-2-mediated suppression of apoptosis. J. Exp. Clin. Cancer Res. 41, 351. 10.1186/s13046-022-02548-2", "ArticleIdList": ["10.1186/s13046-022-02548-2", "PMC9758902", "36527150"]}, {"Citation": "Vallee A., Lecarpentier Y., Guillevin R., Vallee J. N. (2018). Opposite interplay between the canonical WNT/\u03b2-catenin pathway and PPAR gamma: a potential therapeutic target in gliomas. Neurosci. Bull. 34, 573\u2013588. 10.1007/s12264-018-0219-5", "ArticleIdList": ["10.1007/s12264-018-0219-5", "PMC5960455", "29582250"]}, {"Citation": "Verreth W., de Keyzer D., Pelat M., Verhamme P., Ganame J., Bielicki J. K., et al. (2004). Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110, 3259\u20133269. 10.1161/01.CIR.0000147614.85888.7A", "ArticleIdList": ["10.1161/01.CIR.0000147614.85888.7A", "15533870"]}, {"Citation": "Villarroel-Vicente C., Gutierrez-Palomo S., Ferri J., Cortes D., Cabedo N. (2021). Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: an overview. Eur. J. Med. Chem. 221, 113535. 10.1016/j.ejmech.2021.113535", "ArticleIdList": ["10.1016/j.ejmech.2021.113535", "33992930"]}, {"Citation": "Wang W., Xu M. J., Cai Y., Zhou Z., Cao H., Mukhopadhyay P., et al. (2017). Inflammation is independent of steatosis in a murine model of steatohepatitis. Hepatology 66, 108\u2013123. 10.1002/hep.29129", "ArticleIdList": ["10.1002/hep.29129", "PMC5481491", "28220523"]}, {"Citation": "Wild C. P. (2019). The global cancer burden: necessity is the mother of prevention. Nat. Rev. Cancer 19, 123\u2013124. 10.1038/s41568-019-0110-3", "ArticleIdList": ["10.1038/s41568-019-0110-3", "30683893"]}, {"Citation": "Wu G., Liu J., Liu H., Jin L., Huang X., Mo X., et al. (2021). An applicable inflammation-joined and nutrition-related prognostic indicator in patients with colorectal cancer. Front. Oncol. 11, 644670. 10.3389/fonc.2021.644670", "ArticleIdList": ["10.3389/fonc.2021.644670", "PMC8245848", "34221966"]}, {"Citation": "Yamamoto K., Tamura T., Nakamura R., Hosoe S., Matsubara M., Nagata K., et al. (2019). Development of a novel class of peroxisome proliferator-activated receptor (PPAR) gamma ligands as an anticancer agent with a unique binding mode based on a non-thiazolidinedione scaffold. Bioorg Med. Chem. 27, 115122. 10.1016/j.bmc.2019.115122", "ArticleIdList": ["10.1016/j.bmc.2019.115122", "31623970"]}, {"Citation": "Yang P. Y., Zou H., Chao E., Sherwood L., Nunez V., Keeney M., et al. (2016). Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. Proc. Natl. Acad. Sci. U. S. A. 113, 4140\u20134145. 10.1073/pnas.1601653113", "ArticleIdList": ["10.1073/pnas.1601653113", "PMC4839405", "27035989"]}, {"Citation": "Yang J., Zaman M. M., Vlasakov I., Roy R., Huang L., Martin C. R., et al. (2019). Adipocytes promote ovarian cancer chemoresistance. Sci. Rep. 9, 13316. 10.1038/s41598-019-49649-1", "ArticleIdList": ["10.1038/s41598-019-49649-1", "PMC6746782", "31527632"]}, {"Citation": "Zhang H., Zhu S., Chen J., Tang Y., Hu H., Mohan V., et al. (2012). Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 35, 1388\u20131393. 10.2337/dc11-2142", "ArticleIdList": ["10.2337/dc11-2142", "PMC3357218", "22619290"]}, {"Citation": "Zhu X., Xu Y., Wang J., Xue Z., Qiu T., Chen J. (2023). Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer. Front. Immunol. 14, 1165602. 10.3389/fimmu.2023.1165602", "ArticleIdList": ["10.3389/fimmu.2023.1165602", "PMC10106583", "37077909"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "9", "Day": "21"}, {"Year": "2023", "Month": "11", "Day": "6"}, {"Year": "2023", "Month": "12", "Day": "4", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "4", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "12", "Day": "4", "Hour": "4", "Minute": "25"}, {"Year": "2023", "Month": "11", "Day": "15"}], "PublicationStatus": "epublish", "ArticleIdList": ["38044948", "PMC10690586", "10.3389/fphar.2023.1298341", "1298341"]}}], "PubmedBookArticle": []}